10 completed, 7 terminated, 4 recruiting, 2 unknown. 25 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 10, Terminated 7, Recruiting 4, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 11 | Completed 5, Terminated 3, Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow encorafenib: new trials by email Literature Review of encorafenib trials Research Report on encorafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-06-05 | 2026-10-30 |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma Defactinib, Avutometinib, Encorafenib - Cutaneous Melanoma, Brain Metastases | Phase 1 / Phase 2 | Recruiting | University of Utah | 33 | 2024-03-20 | 2025-12-03 |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy Cetuximab, Ulixertinib, Encorafenib - Metastatic Colorectal Cancer | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 27 | 2024-01-18 | 2026-09-11 |
| ZN-c3 in Adult Participants With Metastatic Colorectal Cancer ZN-c3, Encorafenib, Cetuximab - Metastatic Colorectal Cancer | Phase 1 | Terminated | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 44 | 2023-02-27 | 2025-08-08 |
| A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation - Healthy | Phase 1 | Completed | Pfizer | 18 | 2022-07-01 | 2024-02-23 |
| Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg - Metastatic Melanoma, BRAF Gene Mutation | Phase 1 | Recruiting | Rina Plattner | 30 | 2022-06-01 | 2026-02-13 |
| Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors Encorafenib - BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC | Phase 1 | Completed | Pierre Fabre Medicament | 3 | 2021-09-27 | 2024-06-24 |
| A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies ERAS-007, Encorafenib, Cetuximab - Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Erasca, Inc. | 101 | 2021-09-20 | 2026-03-25 |
| Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma encorafenib, nivolumab, ipilimumab - Melanoma | Phase 1 / Phase 2 | Terminated | Jason J. Luke, MD | 2 | 2021-05-28 | 2024-05-23 |
| PF-07284892 in Participants With Advanced Solid Tumors PF-07284892, lorlatinib, binimetinib - Solid Tumor | Phase 1 | Terminated | Pfizer | 53 | 2021-03-17 | 2026-06-04 |
| Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma Encorafenib + Binimetinib - BRAF V600 Mutation, Unresectable Melanoma | Phase 1 | Withdrawn | Pierre Fabre Medicament | 2021-01-21 | 2023-02-21 | |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) Sasanlimab Prefilled syringe, Encorafenib, Binimetinib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | Pfizer | 34 | 2020-11-10 | 2026-01-09 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Binimetinib, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Terminated | University of California, San Francisco | 2 | 2020-08-31 | 2023-01-09 |
| Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma binimetinib, encorafenib - Melanoma | Phase 1 | Terminated | Pfizer | 1 | 2020-08-03 | 2023-04-03 |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE Binimetinib, Encorafenib, Palbociclib - Melanoma, Metastasis | Phase 1 / Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 78 | 2020-06-04 | 2024-01-05 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Binimetinib, Encorafenib - Advanced BRAF Mutant Cancers | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2019-02-14 | 2024-10-21 |
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma Encorafenib, Binimetinib, Pembrolizumab - Malignant Melanoma | Phase 1 / Phase 2 | Completed | Prof. Dr. med. Dirk Schadendorf | 16 | 2018-04-24 | 2021-02-16 |
| Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors losartan, dextromethorphan, caffeine - Advanced Solid Tumors, Metastatic Melanoma | Phase 1 | Completed | Pfizer | 56 | 2018-01-02 | 2024-09-27 |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer LY3214996, Midazolam, Abemaciclib - Advanced Cancer, Metastatic Melanoma | Phase 1 | Completed | Eli Lilly and Company | 210 | 2016-09-29 | 2022-11-22 |
Showing 20 of 25. Sign in to see all of them.
Melanoma (12) · Colorectal Neoplasms (10) · Neoplasm Metastasis (4) · Carcinoma, Non-Small-Cell Lung (3) · Colonic Neoplasms (2) · Gastrointestinal Neoplasms (2) · Rectal Neoplasms (2) · Brain Neoplasms (1) · Digestive System Neoplasms (1) · Disease Progression (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lung Neoplasms (1) · Neurofibromatosis 1 (1) · Pancreatic Neoplasms (1)
Pfizer (7) · Array BioPharma (2) · M.D. Anderson Cancer Center (2) · Pierre Fabre Medicament (2) · Curegenix Inc. (1) · Eli Lilly and Company (1) · Erasca, Inc. (1) · Jason J. Luke, MD (1) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Peter MacCallum Cancer Centre, Australia (1) · Prof. Dr. med. Dirk Schadendorf (1) · Rina Plattner (1) · University of California, San Francisco (1)
United States (20) · Australia (8) · Spain (6) · Italy (5) · Belgium (4) · Canada (4) · France (4) · Netherlands (3) · Germany (2) · Japan (2) · Singapore (2) · Switzerland (2) · Taiwan (2) · China (1) · Czechia (1)
Array BioPharma (1) · Chloe E Atreya, MD, PhD (1) · Christine Parseghian, MD (1) · Dirk Schadendorf, Prof. Dr. (1) · Grant McArthur, Prof (1) · Howard Colman, MD, PhD (1) · Jason J Luke, MD (1) · Joyce Antal (1) · Li Zhang, MD (1) · Petr Arenberger (1) · Rina Plattner, PhD (1)
PMID 31744895, PMID 32669376, PMID 34655839, PMID 35385748, PMID 36811382, PMID 38424308, PMID 38878209, PMID 40578933, PMID 40611889, PMID 42101296
2016 (1), 2018 (1), 2019 (1), R01CA258751 (1), UM1CA186688 (1)